Avenue Therapeutics announced that it has received Notice of Allowance from USPTO (U.S. Patent and Trademark Office) for a new patent application (U.S. Application No. 15/163,111), entitled “Intravenous Administration of Tramadol.”
The patent application describes and claims a dosing regimen of intravenous (IV) 50 mg tramadol that provides certain pharmacokinetic parameters that are similar to those of 100 mg tramadol HCl administered orally every 6 hours at steady state.
Avenue’s Interim CEO, Lucy Lu said that this new patent is a key milestone for them because it solidifies the intellectual property position of their IV tramadol program.
This patent application falls under Avenue’s licensing agreement with Revogenex Ireland Ltd.